Clinical manifestations and management of cryptococcal infection.
S Subramanian, D Mathai
Department of Medicine Unit-I & Infectious Diseases, Christian Medical College, Vellore, Tamilnadu, India
Department of Medicine Unit-I & Infectious Diseases, Christian Medical College, Vellore, Tamilnadu
Cryptococcus neoformans is an important fungal pathogen causing invasive infection, especially of the central nervous system in this era of the HIV/AIDS epidemic. The choice of treatment depends on site(s) of infection and the patient«SQ»s immune status. Use of appropriate antifungal agents decreases mortality significantly, but requires continued therapy and long-term maintenance to prevent relapses. The use of liposomal amphotericin B (L Amp B) has overcome some of the difficulties usually found in this setting. The major advantage of these liposomal formulations are faster clearance of C. neoformans [cerebrospinal fluid (CSF) negative] and a reduction in amphotericin toxicity. The majority of clinical efficacy data related to L Amp B are derived from compassionate use studies and case series. Use of liposomal amphotericin has also shown to be a cost effective approach.
|How to cite this article:|
Subramanian S, Mathai D. Clinical manifestations and management of cryptococcal infection. J Postgrad Med 2005;51:21-26
|How to cite this URL:|
Subramanian S, Mathai D. Clinical manifestations and management of cryptococcal infection. J Postgrad Med [serial online] 2005 [cited 2020 Jan 25 ];51:21-26
Available from: http://www.jpgmonline.com/text.asp?2005/51/5/21/19810
Cryptococcus neoformans is the second most common cause of opportunistic fungal infection in patients with AIDS. Although first isolated in the juice of a fruit by San Felice in 1894, it was shown subsequently in 1901 to be present in natural sources like milk. It has been known to be a pathogen in humans for over 50 years. Various types of soil contaminated with pigeon extracts provide the environmental source of this widely prevalent organism. The high incidence of Cryptococcal meningitis among patients with HIV in Thailand is thought to be explained by the increased shedding of the organism in chicken droppings.
There are two varieties of C. neoformans with different virulence: C. neoformans var neoformans consisting of serotypes A and D, which cause disease in patients with immune suppression and C. neoformans var gatti consisting of serotypes B and C, that cause disease in normal hosts. The organism is usually 4-6 mm in diameter, but in the encapsulated form it can be up to 30 mm.
Virulence is due to production of oxidase and protease enzymes and the antiphagocytic properties of the carbohydrate capsule. Noncapsular mutant forms lack pathogenicity. A host site with abundant carbon dioxide concentration favours capsule bioformation.
Infections occur through inhalation of small diameter (less than 10 mm) yeast like organisms which enter smaller respiratory passages and then remain dormant depending on the host reaction. Organisms are then reactivated from such previous dormant infections in the lung or lymph node, just as in tuberculosis (TB).
A normally functioning host immune response is capable of eliminating this infection, or can sequester C. neoformans into sites where it can remain controlled via fungistatic and fungicidal host defense mechanisms. The humoral system is activated through the complement cascade. Therefore, the clinical manifestations of this infection can range from an asymptomatic colonization of the respiratory tract to a widespread dissemination depending on the host immune factors. As dissemination occurs, the central nervous system (CNS) is commonly involved. The basal meninges of the brain are preferentially affected causing thickening with subsequent invasion of the deeper brain tissues. In the meninges, the organism appears to be suspended in a mucoid material that is derived from the capsule. Dissemination is due to serious defects in cell-mediated immune surveillance. Risk factors include: advanced HIV stage, corticosteroid use, lymphomas, solid organ transplant recipients, and patients with immune suppressive disease or receiving such drugs. Familial cryptococcosis has been reported and is due to genetic defects in the immune system.
The laboratory diagnosis of cryptococcosis is established by the isolation of organism in culture, histopathology, or detection of its polysaccharide capsular antigen in cerebrospinal fluid (CSF). The organism grows in blood and chocolate agar within 3-5 days.
Cytological examination (Papanicolou's stain) of sterile body fluids like CSF and India ink preparation for the negative staining characteristics are useful for identification of the organism. The latter is useful when >10 colony-forming units (CFU)/ml of yeasts are present. Besides India ink, alcian blue, and mucicarmine are the other two stains used to detect the polysaccharide capsule of yeasts in tissue.
Analysis of cerebrospinal fluid (CSF) usually reveals a poor white blood cell (WBC) count, inflammatory response, with a normal or low-CSF glucose levels, and a positive cryptococcal antigen test. The occurrence of cryptococcal antigen in the CSF (detected by latex agglutination) is not through a passive diffusion from serum but via active yeast invasion of the subarachnoid space.
The cryptococcal antigen detection test is not useful in monitoring the course of therapy. However, patients with lower titers ( Brain
Involvement of the parenchyma of the brain and menings occurs in 40-86% of patients as the organism has this unique and unexplained predisposition to establish an infection at these sites. The presentation can be acute or chronic. Nonmeningeal or nonparenchymal brain involvement is uncommon. An acute onset (30 days) onset with headache, fever and nuchal pain suggesting meningeal irritation, occurs as the presenting symptom. However, neither headache nor fever need always be present in HIV-infected patients. Instead they could present with lethargy, obtundation, stupor, coma, or even dementia. Clinical signs lack precision or accuracy in predicting the aetiology in meningitis. Papilloedema may be observed but focal neurological signs such as cranial nerve palsies are rare. Intracerebral, cerebellar, and spinal cord lesions, although rare, have been noted. Complications of CNS involvement include internal hydrocephalus, focal motor deficits, changes in mentation, and symptoms of raised intracranial pressure. As lesions of brain parenchyma present as a ring-enhancing lesion on imaging, it can mimic Toxoplasma gondii .
Coinfection with other pathogens causing CNS infection, notably Mycobacrterium tuberculosis , is reported as a common occurrence in patients with HIV. However, in a prospective study conducted among 105 patients diagnosed to have cryptococcal meningitis at our center, TB infection was not detectable in the CNS or at other sites.
Cryptococcus is the second most common community acquired fungus (excluding Pneumocystis jiroveci ) isolated from the lung after Aspergillus sp. Although the lung is most likely to have been the initial portal of entry and infection, disseminated foci elsewhere with a normal chest X-ray can be seen. It is considered to be a reactivation of prior pulmonary infection (asymptomatic or subclinical carriage), analogous to TB reactivation. A primary pulmonary complex, similar to TB may be seen, or may be coinfected with TB. The localized pulmonary form is found as a solitary or as multiple small nodules in an asymptomatic individual on chest roentgenogram mimicking malignancy and requiring the diagnosis to be confirmed by lung biopsy. Symptoms of acute pneumonia with cough, fever, and lobar pulmonary infiltrates affecting alveoli or a diffuse interstitial pattern, indistinguishable from P. jiroveci infection occurs in patients with AIDS. Very rarely, it can present as an acute respiratory distress syndrome. Pleural effusion without parenchymal lesion is rare. Surgical intervention for a cryptococcal lung lesion is best avoided as local and systemic dissemination can occur.
Other organ systems
In the skin, cryptococcosis occurs as papules, abscesses, cellulitis, acneiform lesions, draining sinuses, or subcutaneous swellings. Skin biopsy is required to confirm the diagnosis, and to differentiate it from molluscum contagiosum, Kaposi's sarcoma, and herpes virus infection. Although, in a laboratory accident cryptococci can be injected directly into the soft tissue causing localized infection, the vast majority are due to dissemination from the lung.
Ocular involvement is seen as choroidal infection and endophthalmitis and can be confused in patients with AIDS with other coinfections such as: cytomegalovirus, T. gondii , or herpes simplex.
Occurrence of osteomyelitis and arthritis, and reports of direct traumatic inoculation into the bone have been reported. Cardiac valvular involvement, both of the native and prosthetic valves, mycotic aneurysms, and myocarditis can occur and sometimes it may cause sudden death. Enlarged adrenal glands on CT imaging of the abdomen should alert the clinician for a possible adrenal insufficiency (or associated histoplasmosis). Cryptococcal pyelonephritis and prostatitis have been reported. However, there have been no reports of sexual route of acquisition of infection.
Rarely, areas of the mucous membranes of mouth, larynx, anal region, skeletal muscle, and placenta have been reportedly infected. Although cryptococci can be isolated from the faeces, the gastrointestinal route of acquisition is unlikely and its affectation besides hepatitis is not known. Hepatitis and peritoneal infection could present as an acute abdominal emergency.,
Cryptococcosis and AIDS
It is the first opportunistic infection that occurs in over a quarter of patients who develop AIDS. About 5-10% of patients with AIDS (CD4 lymphocyte count of et al . have developed an indigenous patient worthy sterile pyrogen-free liposomal preparation (FungisomeTM), which have shown to be safe and effective in cryptococcal meningitis in the dose of 1-3 mg/kg/day. As compared to conventional Amp B, this preparation is infused over a much shorter period requiring a smaller volume, does not require premedication and found to be safe in patients who had developed serious unacceptable toxicity with conventional Amp B. This patient worthy formulation is safe, efficacious, and cheaper than the commercially available formulation of Amp B. Combining Amp B (0.5-1 mg/kg/day) and oral FC (150 mg/kg/day) for 2 weeks as induction therapy followed by oral fluconazole 400 mg/day for 10 weeks is considered the standard treatment regimen for cryptococcal meningitis. This dual therapy has shown sustained clearance of cryptococci from CSF (60%) as compared to Amp B alone (51%). Addition of FC causes side effects like diarrhea, hepatitis, and bone marrow suppression usually in the first 2 weeks in a third of patients. Either, per orally administered itraconazole (400 mg/day) or fluconazole (400 mg/day) for 8 weeks, after initial Amp B therapy, had similar efficacy (70 and 68%). In such patients, dose reduction to 100 mg/kg/day could minimize these. Dose needs to be adjusted for renal dysfunction (creatinine > 2 mg%) and with serum FC levels measured by bioassay, enzymatic means, or by high-pressure lipid chromatography. Longer duration of FC therapy correlates with greater recurrence-free survival.
Fluconazole at 400 mg per day given orally or IV has excellent CSF penetration (60-80% of serum levels achieved), that is found even in the absence of meningeal inflammation. Monotherapy with oral fluconazole at doses of 400 mg daily achieved equivalent success rates with clinical cure in 63% and mycological clearance in cultures within 60-90 days in 76% in African patients with AIDS. Higher doses of up to 800 mg daily may be used in those who fail to improve.
Cryptococcus resistant to Amp B and/or fluconazole are rare, but emergence of resistance to fluconazole has become a concern, and is probably linked to extended maintenance regimen. Over two years (2000-2002), in a laboratory-based surveillance reported from Cambodia, the fluconazole MIC90 rose 8-fold to 96 mg/l with resistance rates increasing from 2.5 to 14%. However, the MIC90 for Amp B remained stable over the period.
Itraconazole penetrates the CSF poorly (like Amp B), but its hydrophobicity ensures drug accumulation in the host cells. Itraconazole combined with oral FC (150 mg/kg/day) had achieved responses in 12 of 13 patients, and appeared to shorten time to cure in a small study. However, in AIDS patients with cryptococcal meningitis, itraconazole alone is less effective than Amp B and FC. Itraconazole at doses of 200-400 mg/day for 4-6 months is used to treat individuals who cannot tolerate fluconazole.
Concern about the azole-polyene antagonism and inadequate clinical data in humans has precluded combination of Amp B with fluconazole. In a recent small trial conducted in Thailand, the combination of Amp B with FC cleared cryptococci from CSF of HIV-infected patients significantly faster as compared to Amp B alone, or in combination with fluconazole, or use of all three drugs simultaneously.
Intraventricular Amp B therapy has been used in patients with a poor prognosis, but the complications associated with multiple injections into the lumbar or cisternal space via subcutaneous reservoirs discourage this intervention. Cryptococcomas of the CNS that present as brain abscesses or mass lesions may rarely require operative intervention.
Although chronic corticosteroid and cyclosporine therapy can predispose patients to cryptococcal infection and impair treatment response, the dose of these drugs need to be modified based on the underlying disease conditions for which they are being used. Patients with previously treated cryptococcal infection can receive solid organ transplantation without reactivating the fungal infection and need for antifungal prophylaxis. Although cryptococcal meningitis has been reported only rarely in pregnant women, both Amp B and FC cross the placental barrier and no case of congenital cryptococcosis has been described.
With Amp B usage, whole blood counts and serum electrolytes need to be monitored weekly. Demonstration of CSF clearance by culture negativity at the end of the second week of therapy is required. Re-examination of the CSF is mandatory in patients who deteriorate and should be repeated at the end of therapy, and at 1, 3, and 6 months post-therapy to detect relapses. Serially done lumbar punctures with drainage of fluid may also serve to reduce the headache in patients with raised intracranial tension (ICT). In a large study, patients with a pretreatment opening pressure 250 mm). Furthermore, lumbar punctures to bring down the pressure by 10 mm in patients with opening pressures of >250 mm was shown to improve clinical response at 2 weeks. However, it should also be kept in mind that at very high-opening pressures, there is a possible risk of cerebellar herniation occuring. Drugs have not been shown to be effective in decreasing the intra cranial pressure. In a small study, the diuretic acetazolamide use was found to have higher risk of adverse effects. There is no data on the utility of steroids in this condition.
Computed tomogram scan to identify hydrocephalus or presence of parenchymal lesions, as the cause of raised ICT may be required. Surgical options are reserved for patients with hydrocephalus or for those with intracerebral lesions. However, in a retrospective review, placement of intracerebral shunt in HIV negative patients with cryptococcal meningitis was found not to be useful.
Lipid-associated amphotericin B formulations are being studied in the treatment of cryptococcal meningitis. Successful treatment outcome in patients with AIDS has been reported. In a retrospective review of the collaborative exchange of antifungal research (CLEAR), use of Amp B lipid complex (ABLC) in a median dose of 4.3 mg/kg/day, achieved a cure in 41 of 47 HIV-infected patients with CNS cryptococcal infection when administered for a median of 13 days. In a randomized open-label trial from Burundi, the use of intralipid Amp B was associated with significantly lower chance of infusion related toxicity (fever and chills) but higher risk of nephrotoxicity as compared to Amp B in dextrose. There was no difference in cure rates between the two groups in this study. In an open label, randomized, comparative phase III safety, and efficacy study with conventional Amp B and L Amp B in patients with systemic fungal infections, use of Fungisome in dose of 1-3 mg/kg/day achieved significant cure in cryptococcal meningitis.. In phase II studies, L Amp LRC-1(Fungisome) achieved a cure in six (85%) of seven cryptococcal meningitis patients. There have been case reports from India of successful treatment of cryptococcal meningitis and long-term recurrence-free survival with liposomal formulations of Amp B (L Amp LRC-1). Newer agents like caspofungin and voriconazole have not been tried in clinical trials for this infection. The role of cytokines to enhance host defense and immunomodulation with transfer factor are under study. A defective production of proinflammatory cytokines - interferon (IFN)-g and tumor necrosis factor have been seen in patients with cryptococcal meningitis. In a recent study, patients with cryptococcal meningitis randomized to receive IFN-g or placebo along with standard therapy (Amp B alone or with FC) showed that patients receiving IFN-g had a significant 2-week culture conversion with a trend toward better mycological and clinical success. Further studies are required to support this, especially as the therapy is well tolerated.
Treatment of asymptomatic pulmonary colonization is unnecessary and at the other end of the spectrum, immunocompromised hosts with cryptococcal meningitis require definite and aggressive therapy. In case of symptomatic pulmonary infection, urinary tract, or cutaneous disease, fluconazole (200-400 mg/day) for 36 months is recommended.
Prevention of relapse
Rapid institution of antifungal treatment reduces mortality. The duration of initial therapy is an area of controversy. Clinical trials suggest that patients with AIDS should get drugs for a longer duration. Relapse rates range from 15 to 25% in non-AIDS patients, and >50% in AIDS patients. Chronic suppressive therapy is now the standard of care in such patients, and oral fluconazole is the most widely used drug. Intravenous Amp B (50 mg) once or twice weekly is effective. Comparative trials to evaluate the long-term management of cryptococcosis among AIDS patients are needed to improve outcome.
Fluconazole at 200 mg daily is recommended for chronic suppression as secondary prophylaxis for patients with AIDS. In trials it has been shown to be more effective and less toxic than Amp B weekly at 1 mg/kg. Oral itraconazole at 200 mg/day successfully prevented relapse of cryptococcal meningitis in 34 of 39 patients with AIDS.
Before the era of highly active antiretroviral therapy (HAART), prophylaxis for cryptococcal meningitis with fluconazole was life long. With a promise of better recovery in immune function, discontinuation of therapy safely in those with sustained (>3 months) undetectable viral loads and a CD4 count >100 cells/ml has been suggested. In a retrospective review of patients, who had discontinued secondary fluconazole prophylaxis among HIV-infected patients on HAART, 4 of 100 patients redeveloped cryptococcal meningitis within 28 months. In three of these patients, the serum cryptococcal antigen became positive at relapse.
Amphotericin B has improved the prognosis in cryptococcal meningitis, an infection that was uniformly lethal earlier. With therapy, less than a quarter of patients die. Poor prognostic factors in cryptococcal meningitis include: presence of visual disturbances, hyponatremia, an initial positive India ink for the pathogen, high-CSF opening pressure, low-CSF glucose, and low-CSF leucocytes ( P. marneffei in those with advanced HIV disease (CD4 less than 100 cells/ml) but this did not result in improved survival. Further studies are required to clarify the issue.
Data from Indian studies
Data from our institution published earlier had suggested a 7% occurrence (4 of 61 patients) of cryptococcal meningitis as the AIDS defining condition at presentation. In another study evaluating the aetiology of prolonged fever in HIV-infected adults, cryptococcosis was detected to be the causative agent in 10% of these patients. Cryptococcal meningitis was reported in 2.5% (12 of 483) of HIV-infected patients from a tertiary institution with a mortality of 50%.
In a 5-year retrospective cohort and 1-year prospective cohort study (total 105 patients) at our center (2000-2001), we assessed clinical profile, outcomes, and poor prognostic markers in patients with cryptococcal meningitis. More than 75% of them were C. neoformans are needed.
|1||Kuroki M, Phichaichumpon C, Yasuoka A, Chiranairadul P, Chosa T, Sirinirund P, et al . Environmental isolation of Cryptococcus neoformans from an endemic region of HIV-associated cryptococcosis in Thailand. Yeast 2004;21:809-12.|
|2||Kwon-Chung KJ, Rhodes JC. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans . Infect Immun 1986;51:218-23.|
|3||Brueske CH. Proteolytic activity of a clinical isolate of Cryptococcus neoformans . J Clin Microbiol 1986;23:631-3.|
|4||Granger DL, Perfect JR, Durack DT. Virulence of cryptococcosis: Regulation of capsule synthesis by carbon dioxide. J Clin Invest 1985;76:508-16.|
|5||Neilson JB, Fromtling RA, Bulmer GS. Cryptococcus neoformans : Size range of infectious particles from aerosolized soil. Infect Immun 1977;17:634-8.|
|6||Diamond RD, May JE, Kane MA, Frank MM, Bennett JE. The role of the classical and alternative complement pathways in host defense against Cryptococcus neoformans infection. J Immunol 1974;112:2260-70.|
|7||Krick JA. Familial cryptococcal meningitis. J Infect Dis 1981;143:133.|
|8||Perfect JR, Durack DT, Gallis HA. Cryptococcaemia. Medicine 1983;62:98-109.|
|9||Cohen J. Comparison of the sensitivity of three methods for the rapid identification of Cryptococcus neoformans . J Clin Pathol 1984;37:332-4.|
|10||Eng RH, Chmel H, Corrado M. The course of cryptococcal capsular polysaccharide antigenemia/human cryptococcal polysaccharide elimination kinetics. Infection 1983;11:132-6.|
|11||Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study of 111 cases. Ann Intern Med 1974;80:176-81.|
|12||Aberg JA, Watson J, Segal M, Chang LW. Clinical utility of monitoring serum cryptococcal antigen titers in patients with AIDS-related cryptococcal disease. HIV Clin Trials 2000;1:1-6. |
|13||Fujita NK, Reynard M, Sapico FL, Guze LB, Edwards JE Jr. Cryptococcal intra cerebral mass lesions: the role of computed tomography and nonsurgical management. Ann Intern Med 1981;94:382-8.|
|14||Perfect JR. Cryptococcosis. In : Systemic Fungal Infections: Diagnosis and treatment II. Infect Dis Clin North Am 1989;3:77-102.|
|15||Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 1981;94:611-6.|
|16||Gal AA, Koss MN, Hawkins J, Evans S, Einstein H. The pathology of pulmonary cryptococcal infections in the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1986;110:502-7.|
|17||Sabeta JR, Andriole VT. Cryptococcal infection of the central nervous system. Med Clin North Am 1985;69:333-44.|
|18||Steiner I, Polacheck I, Melamed E. Dementia and myoclonus in a case of cryptococcal encephalitis. Arch Neurol 1984;41:216-7.|
|19||Baker RD. The primary pulmonary lymph node complex of cryptococcosis. Am J Clin Pathol 1976;65:83-92.|
|20||Young EJ, Hirsh DD, Fainstein V, Willaims TW. Pleural effusions due to Cryptococcus neoformans : A review of the literature and report of two cases with cryptococcal antigen determination. Am Rev Respir Dis 1980;121:743-7.|
|21||Campbell DG. Primary pulmonary cryptococcosis. Am Rev Respir Dis 1966;94:236-43.|
|22||Rico MJ, Penneys NS. Cutaneous cryptococcosis resembling molluscum contagiosum in a patient with AIDS. Arch Dermatol 1985;121:901-2.|
|23||Glaser JB, Garden A. Inoculation of cryptococcosis without transmission of the acquired immunodeficiency syndrome. N Engl J Med 1985;313:266.|
|24||Crump JR, Elner SG, Elner VM, Kaufman CA. Cryptococcal endophthalmitis: case report and review. Clin Infect Dis 1992;14:1069-73. |
|25||Bayer AS, Choi C, Tillman DB, Guze LB. Fungal arthritis: V. Cryptococcal and histoplasmal arthritis. Semin Arth Rheum 1980;9:218-27. |
|26||Morris E, Wolinsky E. Localized osseous cryptococcosis: A case report J Bone Joint Surg 1965;47:1027-9.|
|27||Colmers RA, Irniger W, Steiberg DH. Cryptococcus neoformans endocarditis cured by amphotericin B. JAMA 1967;199:762-4.|
|28||Boden WE, Fisher A, Medeiros A, Benham I, McEnany MT. Bioprosthetic endocarditis due to Cryptococcus neoformans . J Cardiovasc Surg 1983;24:164-6.|
|29||Rigdon RH, Kirksey OT. Mycotic aneurysm (cryptococcosis) of the abdominal aorta. Am J Surg 1952;84:486-91.|
|30||Lewis N, Lipsick J, Cammarosano C. Cryptococcal myocarditis in acquired immunodeficiency syndrome. Am J Cardiol 1985;55:1240.|
|31||Rupali P, Subramanian S, Abraham OC, Mathai D. Disseminated histoplasmosis. In press. |
|32||Randall JE Jr, Stacy WK, Toone EC, Prout GR Jr, Madge GE, Shadomy HJ, et al . Cryptococcal pyelonephritis. N Engl J Med 1968;279:60-5.|
|33||Huynh MT, Reyes CV. Prostatic cryptococcosis. Urology 1982;20:622-3.|
|34||Procknow JJ, Benfield JR, Rippon JW, Diener CF, Archer FL. Cryptococcal hepatitis presenting as a surgical emergency. JAMA 1965;191:269-74.|
|35||Watson NE Jr, Johnson AH. Cryptococcal peritonitis. South Med J 1973;66:387-8.|
|36||Kovacs JA, Kovacs AA, Polis M, Wright WC, Gill VJ, Tuazon CU, et al . Cryptococcosis in acquired immunodeficiency syndrome. Ann Intern Med 1985;103:533-8.|
|37||Drutz DJ, Spickard A, Rogers DE, Koenig MG. Treatment of disseminated mycotic infections: A new approach to amphotericin B therapy. Am J Med 1968;45:405-18.|
|38||Kshirsagar NA, Kirodian BG. Liposomal Drug Delevery System from Laboratory to Patients: Our Experience Proc. Indian Natn Sci Acad 2002;B68:333-48|
|39||van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al . Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Eng J Med 1997;337:15-21.|
|40||Dupont B, Drouhet E. Cryptococcal meningitis and fluconazole. Ann Intern Med 1987;106:778.|
|41||Laroche R, Dupont B, Touze JE, Tealman H, Bogaerts J, Kadio A, et al . Cryptococcal meningitis associated with acquired immunodeficiency syndrome (AIDS) in African patients: Treatment with fluconazole. J Med Vet Mycol 1992;30:71-8.|
|42||Berry AJ, Rinaldi MG, Graybill JR. Use of high dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother 1992;36:690-2. |
|43||Sar B, Monachy D, Vann M, Keo C, Sarthou JI, Buisson Y. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 2004;54:563-5. Epub 2004 Jul 14.|
|44||Viviani MA. Opportunistic fungal infections in patients with acquired immunodeficiency syndrome. Chemotherapy 1992;38:35-42.|
|45||Brouwer AE, Rajanuwong A, Cheirakul W, Griffin GE, Larsen RA, White NJ, et al . Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial. Lancet 2004;363:1764-7.|
|46||Iitaka K, McEnery PT, West CD. Successful renal transplantation after generalized cryptococcosis. J Pediatr 1978;92:422-3.|
|47||Stafford CR, Fisher JF, Fadel HE, Espinel-Ingroff AV, Shadomy S, Hamby M. Cryptococcal meningitis in pregnancy. Obstet Gynecol 1983;62:35s-7s.|
|48||Graybill JR, Sobel J, Saag M, van der Horst C, Powderly W, Cloud G, et al . Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis 2000;30:47-54.|
|49||Antinori S, Ridolfo AL, Gianelli E, Piazza M, Gervasoni C, Monforte AA. The role of lumbar puncture in the management of elevated intracranial pressure in patients with AIDS-associated cryptococcal meningitis. Clin Infect Dis 2000;31:1309-10.|
|50||Newton P, Thai LH, Tip NQ, Short JM, Chierakul W, Rajanuwong A, et al . A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002;35:769-72.|
|51||Liliang PC, Liang CL, Chang WN, Chen HJ, Su TM, Lu K, et al . Shunt surgery for hydrocephalus complicating cryptococcal meningitis in human immunodeficiency virus-negative patients. Clin Infect Dis 2003;37:673-8. |
|52||Badour LM. with the Collaborative Exchange of Antifungal Research (CLEAR) steering committee. Early response to ABLC among patients with CNS cryptococcal infections. Blood 2000;96:438A.|
|53||Joly V, Aubry P, Ndayiragide A, Carrire I, Kawa E, Mlika-Cabanne N, et al . Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996;23:556-62.|
|54||Bodhe PV, Kotwani RN, Kirodian BG, Kshirsagar NA, Pandya SK. Open label, randomized, comparative Phase III safety and efficacy study with conventional Amphotericin B and Liposomal Amphotericin B in patients with systemic fungal infection. JAPI 2002;50:662-70. |
|55||Kotwani RN, Gokhale PC, Bodhe V, Kirodan BG, Kshirsagar NA. Safety and efficacy of liposomal amphotericin B in patients with cryptococcal meningitis. J Assoc Physicians India 2001;49:1086-90.|
|56||Pappas PA, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, et al . Recombinant Interferon-γ1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004;189:2185-91.|
|57||Powderly WG, Keath EJ, Little JR, et al . Resistant Cryptococcus neoformans in a patient with AIDS [abstract 1164]. Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Atlanta, Georgia, October 21-24, 1990.|
|58||Mussini C, Pezotti P, Mirü JM, Martinez E, de Quiros JC, Cinque P, et al . Discontinuation of maintainance therapy for cryptococcal meningitis in patients with AIDS treated with highly active anti retroviral therapy: an international observational study. Clin Infect Dis 2004;38:565-71. |
|59||Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med 2004;5:140-3. |
|60||Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002;34:277-84. Epub 2001 Dec. |
|61||Chacko S, John TJ, Babu PG, Jacob M, Kaur A, Mathai D. Clinical pofile of AIDS in India: a review of 61 cases. J Assoc Physicians India 1995;43:535-8.|
|62||Rupali P, Abraham OC, Zachariah A, Subramanian S, Mathai D. Aetiology of prolonged fever in antiretroviral-naοve human immunodeficiency virus-infected adults. Nat Med J India 2003;16:193-9.|
|63||Jaiswal SP, Hemwani N, Sharma N, Athale S, Chitnis DS. Prevalence of fungal meningitis among HIV positive & negative subjects in Indore (MP state). Indian J Med Sci 2002;56:325-9.|
|64||Kalra SP, Chadha DS, Singh AP, Sanchete PC, Mohahaptra AK. Cryptococcal meningitis in acquired immunodeficiency syndrome. J Assoc Physicians India 1999;47:958-61.|
|65||Khanna N, Chandramuki A, Desai A, Ravi V. Cryptococcal infection of the central nervous system: an analysis of predisposing factors, laboratory findings and outcome in patients from south India with special reference to HIV infection. J Med Microbiol 1996;45:376-9. |
|66||Chakrabarti A, Sharma A, Sood A, Grover R, Sakhuja V, Prabhakar S, et al . Changing scenario of cryptococcosis in a tertiary care hospital in north India. Indian J Med Res 2000;112:56-60.|